Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE DM versus TAVIST ALLERGY SINUS HEADACHE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE DM versus TAVIST ALLERGY SINUS HEADACHE.
PROMETHAZINE DM vs TAVIST ALLERGY/SINUS/HEADACHE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
TAVIST ALLERGY/SINUS/HEADACHE contains clemastine fumarate (first-generation antihistamine) that competitively antagonizes histamine at H1 receptors, and acetaminophen that inhibits cyclooxygenase (COX) enzymes in the CNS, reducing prostaglandin synthesis and fever; phenylpropanolamine is an alpha-adrenergic agonist that causes vasoconstriction of nasal mucosa.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
1 tablet (acetaminophen 500 mg, diphenhydramine 12.5 mg, phenylephrine 10 mg) orally every 4-6 hours as needed; maximum 4 tablets per day
None Documented
None Documented
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
5-7 hours for clemastine; 12-15 hours for pseudoephedrine; acetaminophen half-life 2-3 hours. Context: Clemastine half-life supports twice-daily dosing; pseudoephedrine's longer half-life allows 6-8 hour dosing intervals
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Renal excretion of unchanged drug and metabolites accounts for 70-80%, with 15-25% fecal elimination; bilary excretion contributes to remaining
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine/Decongestant Combination